Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Sanofi 2 ADR Representing Ord Shs SNY

Healthcare
Sanofi SA is a France-based healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:SNY)

Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD

GlobeNewswire 1 day ago

Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

GlobeNewswire 1 day ago

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024

GlobeNewswire May 13, 2024

Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy

GlobeNewswire May 13, 2024

Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis (CRSwNP)

GlobeNewswire May 13, 2024

Novavax and Sanofi Announce Co-exclusive Licensing Agreement to Co-commercialize COVID-19 Vaccine and Develop Novel COVID-19-Influenza Combination Vaccines

PR Newswire May 10, 2024

Dupixent® (dupilumab) FDA Approved as First and Only Treatment Indicated for Children Aged 1 Year and Older with Eosinophilic Esophagitis (EoE)

GlobeNewswire January 25, 2024

Inhibrx Announces Sale of INBRX-101 to Sanofi for an aggregate value of up to $2.2B

PR Newswire January 23, 2024

Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment

Business Wire November 30, 2023
View More News ››

Opinion & Analysis (NDAQ:SNY)

Translate Bio and Sanofi Expand Partnership to Develop mRNA Vaccines

Streetwise Reports June 24, 2020

Regeneron Reports Positive Phase 3 Dupixent Data; Gains EU Approval Recommendation

Streetwise Reports September 24, 2019
View More Opinion ››

Bullboard Posts (NDAQ:SNY)

Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sal

Breaking News: $SNY Drugmaker Sanofi's Strong Dupixent And Beyfortus Vaccine Sales Propel Q1 Earnings | BenzingaThursday,@Sanofi SA@...
whytestocks - April 25, 2024

Sanofi and Covid19? WPD Pharma...

Sanofi could easily buy WPD Pharma, who develop a Covid19-drug called WP1122. Did you read this? https://www.globenewswire.com/news...
Blocky - January 8, 2021

Happy new year Do your Own DD

https://www.globenewswire.com/news-release/2020/12/31/2151927/0/en/MedMira-Announces-Product-Update.html
Rossaporino - January 2, 2021

Bonvoyage12.....Lying Pumper

Ignore this clown as he posts lies trying to mislead investors about the actual state of the company...he also posts this same BS on...
Mil_Man54 - December 26, 2020

Vaccine Stocks - Can the President Overrule the FDA?

An approval cycle that typically takes years is being expedited. In the case of the 2020 pandemic, the FDA  has shortened standard...
schoolofrock - October 7, 2020

Room to run?

Tough market these days but.... Hydroxyquinoline for potential covid co-treatment And now the vaccine deal... Seems promising ...
Gbathat - March 27, 2020
View more Bullboard ››

Steppe Gold Ltd

Steppe Gold Ltd

Steppe Gold Ltd. is engaged in the business of precious metals and minerals exploration sector. Its project includes Altan ...
View More »